Navigation Links
HistoRx Announces First Clinical Diagnostic Use of AQUA® Technology
Date:11/12/2010

BRANFORD, Conn., Nov. 12, 2010 /PRNewswire/ -- HistoRx, Inc. (privately held), a diagnostics company, announced the launch and first commercial sale this week of clinical diagnostic assays based on AQUA® technology.  Genoptix, Inc. (Nasdaq: GXDX), a specialized laboratory service provider, is launching NexCourse®(1) BCa by AQUA technology, a suite of breast cancer assays based on quantitative immunohistochemistry.  NexCourse BCa by AQUA technology is:

  • More reproducible than traditional IHC testing, for confidence in determining appropriate therapy
  • Minimizes receptor status false-negative results by utilizing an objective, quantified score for protein expression that provides more accurate results; and
  • Ideal for confirmatory testing of ER/PR/HER2 status prior to hormonal therapy, antibody-based therapy and/or chemotherapy when initial results are inconclusive or negative.

Genoptix and HistoRx signed a multi-year licensing agreement for AQUA® technology and several diagnostic assays based on it in February 2010; the first commercial use announced today triggers a key milestone payment outlined in the agreement.  Genoptix obtained exclusive commercial laboratory rights in the United States to develop and perform estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) assays using HistoRx's proprietary technology.  Misclassification of receptor status by IHC is common:  several studies have shown that false-positive and false-negative ER/PR/HER2 results occur regularly in laboratories around the country and around the world.  Inaccurate results may affect treatment decisions, excluding patients from use of potentially efficacious therapies or inappropriately subjecting patients to therapies known to cause serious adverse events.

"HistoRx is delighted to announce the first availability of AQUA® technology for clinical diagnostics, and pleased that the breast cancer community will be the immediate beneficiaries of the quantification and reproducibility of measurement inherent in NexCourse BCa by AQUA technology," said Rana K. Gupta, CEO of HistoRx.  "Genoptix has gained the trust of community oncologists and their patients by offering high quality laboratory testing, and HistoRx couldn't think of a more appropriate inaugural partner for commercialization of these assays."

"Peer-reviewed literature shows that conventional IHC-based technology can misclassify ER/PR/HER2 receptor status," said Mike Nerenberg, Senior Vice President and Chief Technology Officer at Genoptix.  "AQUA technology is noted for its reproducible quantitation of protein biomarkers in tissue, and can therefore give oncologists confidence when determining the appropriate therapy for their breast cancer patients."

AQUA technology quantifies tumor markers in designated areas of interest, an important component of the assessment of solid tumors for individual cancer patients.

About HistoRx, Inc.

HistoRx, Inc. is a leading developer of tissue-based diagnostic solutions to advance individualized patient care. The company's products and services are based on proprietary analysis of tissue biomarkers using AQUA® technology. AQUA® technology is the only platform capable of precisely measuring protein biomarker concentration with sub-cellular resolution in tissue sections, enabling fully objective, standardized, reproducible, and automated analysis to guide drug development and therapeutic decision-making. HistoRx is commercializing a pipeline of proprietary diagnostic products targeting improved treatment decision-making and patient outcomes in cancer care. For more information, please visit www.historx.com.

About Genoptix, Inc.

Genoptix is a leading specialized laboratory service provider focused on delivering personalized and comprehensive diagnostic services to its physician customers, community-based hematologists and oncologists. On the forefront of personalized diagnostic services, Genoptix's highly trained group of pathologists utilize sophisticated technology to provide integrated testing and actionable diagnostic reports. Its primary diagnostic services are designed to optimize the care of patients suffering from hematomalignancies, or cancers of the blood and bone marrow, and solid tumors. Founded in 1999, Genoptix completed its initial public offering in November 2007 and is headquartered in Carlsbad, California. For more information, please visit www.genoptix.com.

(1) NexCourse® is a registered trademark of Genoptix, Inc.


'/>"/>
SOURCE HistoRx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. HistoRx Recognized as a 2010 Company to Watch by the Connecticut Technology Council
2. HistoRx and Radiation Therapy Oncology Group Initiate Brain Tumor Biomarker Research Partnership
3. Misonix Announces New Distribution Agreement for South Africa
4. WuXi PharmaTech Announces Shareholder Resolutions Adopted at 2010 Annual General Meeting
5. Winner Medical Announces Preliminary Fiscal Fourth Quarter 2010 Results
6. InfraReDx Announces Presentation of LipiScan™ Research at American Heart Association Scientific Sessions 2010
7. Cardica Announces Fiscal 2011 First Quarter Financial Results
8. Jazz Pharmaceuticals Announces Presentation at the Lazard Capital Markets Healthcare Conference on November 17
9. Bionovo Announces Third Quarter 2010 Highlights and Financial Results
10. Dehaier Medical Announces Conference Call to Discuss Third Quarter 2010 Financial Results
11. Dynatronics Announces Fiscal First Quarter Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/3/2017)...  Eli Lilly and Company (NYSE: ... Phase 3 MONARCH 2 study showed that abemaciclib, ... combination with fulvestrant, significantly improved progression-free survival (PFS) ... with hormone-receptor-positive (HR+), human epidermal growth factor receptor ... or progressed after endocrine therapy (median PFS, 16.4 ...
(Date:5/30/2017)... May 30, 2017 DarioHealth Corp. (NASDAQ: DRIO), a leading ... today announced that it will be presenting at the 7th annual ... PT. Erez Raphael , CEO, of DarioHealth will be giving ... be held on June 6th & 7th, 2017 at the Luxe ... small / micro-cap space. About ...
(Date:5/29/2017)... 29, 2017  Cellect Biotechnology Ltd. (NASDAQ: ... enables the functional selection of stem cells, today provided ... first quarter ended March 31 st , 2017. ... in the first quarter of 2017," said Dr. Shai ... announced the treatment of the first blood cancer patient ...
Breaking Medicine Technology:
(Date:6/28/2017)... ... June 28, 2017 , ... Schneider Insurance ... assistance to clients in southern Montana, is announcing a focused charity effort to ... The outreach programs offered by Zoo Montana provide students with current knowledge on ...
(Date:6/28/2017)... ... June 28, 2017 , ... Designers ... to communities in northern Virginia and DC, is announcing a cooperative charity event ... with Alzheimer’s and other disorders that lead to memory impairment. , The Insight ...
(Date:6/27/2017)... ... 27, 2017 , ... Excel Medical, the leader in Next-Generation ... of Executive Vice President, Sales and Marketing. Finnegan is a widely known industry ... sales leadership. He has received industry recognition for innovations and new approaches to ...
(Date:6/27/2017)... PA and London UK (PRWEB) , ... June 27, 2017 , ... ... applying to a clinical study is whether they can trust the sponsor to pay ... it is vital that sponsors and CROs establish payment strategies that encourage sites to ...
(Date:6/27/2017)... ... 27, 2017 , ... Salucro, the cloud-based payment platform that ... hospitals and provider groups, has announced that it will now offer Parasail’s payment ... a San Francisco health-finance startup that has launched a series of tech-based products ...
Breaking Medicine News(10 mins):